Danaher Is One of the Big Winners From COVID-19
Another quarter, and yet another great set of results from Danaher (NYSE: DHR). The company had a blowout quarter, with 14% core revenue growth driven by very strong growth in its COVID-19 related solutions in life sciences and diagnostics. Moreover, there's reason to believe the pandemic has enhanced the company's long-term growth prospects. Let's take a look at what's going on and whether it's enough to make the stock a buy.
The investment case for the healthcare-focused stock is based on three interconnected factors:
To put some color on the discussion below, here's a look at where the growth came from in the third quarter. As you can see in the chart, it's the medically focused segments that have led the recovery, so let's focus on them.
Source Fool.com
